Cizzle Bio, Inc. Partners with Moffitt Cancer Center to Advance Lung Cancer Detection

Cizzle Bio, Inc. is excited to announce a new collaboration with the Moffitt Cancer Center, the leading cancer treatment and research institution in Florida. This partnership marks a pivotal moment for Cizzle Bio as it moves to clinically evaluate its CIZ1B biomarker test for early-stage lung cancer detection in patients with suspicious lung nodules.

Key Highlights:

• Clinical Evaluation with Moffitt Cancer Center:

  As part of Moffitt’s lung cancer screening program, the CIZ1B biomarker test will be evaluated for its ability to distinguish between cancerous and non-cancerous lung nodules. This is the first time CIZ1B will be tested in such a major clinical setting.

• Using New Monoclonal Antibodies:

  The study will utilize newly developed monoclonal antibodies, produced in collaboration with BBI Solutions, to enhance the test’s accuracy.

• Future Clinical Collaborations:

  This partnership, facilitated by Cizzle Bio’s growing presence in the USA, opens doors for further collaborations with leading cancer centers to bring this innovative test to market.

Why It Matters:

Early detection is crucial in the fight against lung cancer, and the CIZ1B biomarker test could offer a new tool to improve screening accuracy, reduce false positives, and better identify high-risk patients. This collaboration with Moffitt Cancer Center, known for its excellence in lung cancer care, positions Cizzle Bio to play a significant role in enhancing lung cancer diagnostics.

Leadership Insight:

Allan Syms, Executive Chairman of Cizzle Biotechnology, remarked, "Collaborating with Moffitt Cancer Center is a transformative step in our journey to provide a more reliable diagnostic tool for early-stage lung cancer, potentially saving lives and improving outcomes."

Stay tuned for more updates as Cizzle Bio continues to innovate and expand its reach in the fight against lung cancer.

For more information, visit London Stock Exchange.